LSBio
Products
  • Antibodies
  • All Antibodies
  • Primary Antibodies
  • Secondary Antibodies
  • IHC-plus Antibodies
  • Isotype Control Antibodies
  • ELISA and Assay Kits
  • All Kits
  • Assay Kits
  • Traditional ELISA Kits
  • Cell-Based ELISA Kits
  • DNA-Binding ELISA Kits
  • Phospho-Specific ELISA Kits
  • ELISA Development Kits
  • Chemiluminescent CLIA Kits
  • Proteins
  • All Proteins
  • Recombinant Proteins
  • Native Proteins
  • Over-expression Lysates
  • Cell and Tissue Lysates
  • Bio-active Proteins
  • Animal-free Proteins
  • Synthetic Peptides
  • Biochemicals
  • All Biochemicals

  • Immunohistochemistry
  • Comprehensive IHC Reports
  • Custom IHC Services
  • TCR Screening Services
  • IHC-plus Antibodies
Services
  • Immunohistochemistry Services

  • Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.

  • TCR Screening Services

  • Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Have a question? CustomerSupport@LSBio.com
Resources
  • Purchasing
  • Product Ordering Terms and Conditions
  • Holiday Schedule
  • About the LSBio Guarantee
  • About Our Rewards Program
  • Reference Material
  • About LSBio (LifeSpan BioSciences Inc.)
  • About Our 2-million Specimen Tissue Bank
  • About Our IHC Validation Process
  • About Our IHC-plus™ Immunohistochemistry Protocol
  • Protocols
  • Secure Logins
  • Login to Our Secure ShareFile Site
  • Login to Our IHC Database
Distributors
Contact Us

LSBio
2401 Fourth Avenue Suite 900
Seattle WA 98121

Phone: 866-819-4732 (Toll Free North America)
206-374-1102 (International)

Fax: 866-206-6909 (Toll Free North America)
206-577-4565 (International)
How to Buy - Details about how to buy our products.

Orders@LSBio.com - To submit a new order.

Customer.Support@LSBio.com - To submit questions about existing orders, pricing, availability, bulk quotes, proforma invoice requests, or other billing issues.

Technical.Support@LSBio.com - To request technical information requests about an LSBio product or its application.

Sales@LSBio.com - To request information about fee-for-service contract IHC studies, IHC reports, distribution agreements, or general business development.

Worldwide Distributors List - To find your local distributor if you're not within the United States.
Login ▾
Wish List
View Cart

Fingolimod (CAS 162359-55-9) LS-H82

S1P1 receptor agonist, S1P4 receptor agonist, S1P5 receptor agonist
LS-H82-5 / 5 mg / $195
LS-H82-10 / 10 mg / $215
LS-H82-25 / 25 mg / $295
LS-H82-50 / 50 mg / $405
USA Shipment Only
Order Button
100% Guaranteed 100% Guaranteed

Description: Sphingosine 1-phosphate (S1P) is an extracellular lipid mediator whose major effects are mediated through four of the S1P receptors (S1P1, S1P3, S1P4, and S1P5). S1P1 plays a key role in the immune system, regulating lymphocyte egress from lymphoid tissues into the circulation. S1P receptors have been shown to influence cell proliferation, morphology, and migration and are also expressed on a wide range of cells that are involved in many biological processes relevant to multiple sclerosis (MS). Fingolimod (FTY720 (free base) of Item No.) is a derivative of the fungal metabolite myriocin, a structural analog of sphingosine. In vivo, fingolimod is phosphorylated to form fingolimod-phosphate, which resembles naturally occurring S1P. Fingolimod-phosphate functions as an agonist at S1P1, S1P4, and S1P5 receptors (EC50 values of ~0.3-0.6 nM in vitro) and at 10-fold higher concentrations at S1P3 receptors (EC50 values of ~3 nM) but has no activity at S1P2 receptors. Fingolimod is a first-in-class orally bioavailable compound that has shown efficacy in advanced clinical trials for the treatment of MS through receptor-mediated actions both on the immune system and in the central nervous system.<a class="blurbReference" rel="#refer H82_ChemicalStructureImage.png
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
FTY720 (freebase)
biochemical, chemical, agonist
LS-H82
162359-55-9
C19H33NO2
≥98%
A crystalline solid
 
OCC(N)(CO)CCC1=CC=C(CCCCCCCC)C=C1
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
KKGQTZUTZRNORY-UHFFFAOYSA-N
Shipped Ambient, store at -20°C, ≥ 2 years shelf life.
This product is for research use only. Not for administration to humans, or for human or veterinary diagnostic or therapeutic use.
Data Sheet DataSheet    SDS SDS
Related Products: S1PR1 / EDG1 / S1P1 related products

Usage Information

Fingolimod is supplied as a crystalline solid. A stock solution may be made by dissolving the fingolimod in the solvent of choice. Fingolimod is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of fingolimod in these solvents is approximately 5, 10, and 20 mg/ml, respectively. Fingolimod is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

References:
  1. Huwiler, A., Kolter, T., Pfeilschifter, J., et al. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta 1485, 63-99 (2000).
  2. Chun, J. and Hartung, H.P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33(2), 91-101 (2010).
  3. Brinkmann, V., Billich, A., Baumruker, T., et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9(11), 883-897 (2010).

Get Social With Us! Follow us on Facebook Follow us on Google+ Follow us on LinkedIn PSL Alliance Member
Copyright © 2017 LifeSpan BioSciences, Inc. All Rights Reserved Privacy Policy
Catalog Number